Targets › CD200
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2032.
Costimulates T-cell proliferation. May regulate myeloid cell activity in a variety of tissues. (UniProt, P41217)
Open in Phaseline: the race on CD200, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beat AML, LLC | Samalizumab (BAML-16) OX-2 membrane glycoprotein inhibitor | CD200 | Phase 2 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Dec 2032 |
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia (1)
mixed (1)
Beat AML, LLC (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.